Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05188664




Registration number
NCT05188664
Ethics application status
Date submitted
8/12/2021
Date registered
12/01/2022
Date last updated
18/12/2023

Titles & IDs
Public title
Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Scientific title
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Secondary ID [1] 0 0
LM302-01-201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumor 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - LM-302
Treatment: Drugs - Toripalimab

Experimental: LM-302 monotherapy dose escalation - LM-302 monotherapy dose escalation (part Ia). Accelerated titration combined with traditional 3+3 design will be used for monotherapy dose escalation (part Ia).

Experimental: LM-302 in combination therapy dose escalation - LM-302 in combination therapy dose escalation (part Ib).Accelerated titration combined with traditional 3+3 design will be used for LM-302 in combination with fixed dose Toripalimab dose escalation (part Ib).

Experimental: LM-302 Dose Expansion - SMC will select appropriate dose(s) and/or tumor types for dose expansion study.


Treatment: Drugs: LM-302
LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks?

Treatment: Drugs: Toripalimab
Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
DLT
Timepoint [1] 0 0
Cycle 1 of each cohort. Duration of one cycle is 21 days
Primary outcome [2] 0 0
RP2D
Timepoint [2] 0 0
Up to 6 months
Primary outcome [3] 0 0
OBD
Timepoint [3] 0 0
Up to 6 months
Primary outcome [4] 0 0
MTD
Timepoint [4] 0 0
Up to 21 days

Eligibility
Key inclusion criteria
1. Subjects who are fully informed of the purpose, nature, method and possible adverse
reactions of the study, and are willing to participate in the study and sign the
informed consent form (ICF) prior to any procedure.

2. Aged =18 years old when sign the ICF, male or female.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and no
deterioration within 2 weeks prior to the first dose.

4. Life expectancy = 3 months.

5. Subjects must have histological or cytological confirmation of recurrent or refractory
advanced solid tumors, and have progressed on standard therapy, or are intolerable for
available standard therapy, or there is no available standard therapy.

6. CLDN18.2 test should be performed for the enrolled subjects if the archived tumor
tissue samples are available.

7. At least one measurable lesion for phase II dose expansion, according to RECIST v1.1
as assessed by the investigator.

8. Subjects must show appropriate organ and marrow function in laboratory examinations
within 7 days prior to the first dose:

1. Bone marrow reserve: Platelet count (PLT) = 90 × 109/L; Absolute neutrophil count
(ANC) = 1.5 × 109/L; Haemoglobin = 9 g/dL, without receiving EPO, G-CSF, or
GM-CSF within 14 days and blood transfusion including red blood cell and platelet
transfusion in at least 7 days prior to first dose.

2. Coagulation function: INR = 1.5; APTT = 1.5 × ULN.

3. Liver function: Total bilirubin = 1.5 × ULN (Subjects with Gilbert's Syndrome are
allowed if total bilirubin = 3 × ULN); AST and ALT = 2.5 × ULN without liver
metastases (= 5 × ULN if liver metastases are present); Albumin = 2.5 g/dL.

4. Kidney function: Serum creatinine = 1.5 × ULN, or creatinine clearance = 50
mL/min.

5. Cardiac function: Left ventricular ejection fraction (LVEF) = 50%; QT interval
(QTcF) = 480 ms.

9. Subjects who are able to communicate well with investigators and understand and adhere
to the requirements of this study.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participate in any other clinical trial within 28 days prior to 1st dosing of
investigational medicinal product (IMP).

2. Subjects with anti-tumor treatment within 21 days prior to 1st dosing of IMP,
including radiotherapy, chemotherapy, biotherapy, endocrine therapy and immunotherapy,
etc. the following treatments have different time limits:

1. Local small-scale palliative radiotherapy (bone metastasis radiotherapy to
control pain) within 14 days prior to 1st dosing.

2. Oral anti-tumor therapy, including fluorouracil antitumor drugs and small
molecular targeted drugs, etc. within 14 days or 5 half-lives of the drug
(whichever is longer) prior to 1st dosing.

3. Traditional herbal medicine with anti-tumor indication within 14 days prior to
1st dosing.

4. Nitrosourea or Mitomycin C within 42 days prior to 1st dosing.

3. Subjects who experienced grade 3 or higher hypersensitivity to the treatment that
contains monoclonal antibody, e.g., monoclonal antibody therapy, ADC etc.

4. Subjects who were intolerable to the treatment with MMAE based ADCs or anti-CLDN18.2
antibodies, but they can be enrolled if they were tolerable to the treatments and have
experienced a 28-day's washout period prior to 1st dosing of IMP.

5. Subjects who were intolerable to the immunotherapy targeting PD-1 receptor, or its
ligand PD-L1.

6. Any adverse event from prior anti-tumor therapy has not yet recovered to = grade 1 of
CTCAE v5.0.

7. Administrate strong inhibitors/strong inducers of CYP3A4 within 14 days prior to 1st
dosing of IMP.

8. Subjects who take systemic corticosteroids (> 10 mg daily prednisone equivalents) or
other systemic immunosuppressive medications.

9. Pre-existing peripheral sensory or motor neuropathy = Grade 2.

10. Subjects with uncontrolled pain. Subjects requiring analgesic treatment must be on a
stable regimen before participating in the study.

11. Subjects with known central nervous system (CNS) or meningeal metastasis.

12. Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites
requiring recurrent drainage procedures.

13. Subjects with known active keratitis or corneal ulcerations.

14. Use of any live attenuated vaccines within 28 days prior to 1st dosing of IMP.

15. Subjects with the history of idiopathic pulmonary fibrosis, organizing pneumonia.

16. Subjects with the known history of autoimmune disease.

17. Subjects who are taking therapeutic doses of anticoagulants.

18. Subjects with gastric outlet obstruction, persistent recurrent vomiting or
uncontrolled/severe gastrointestinal hemorrhage, or ulcer within 28 days prior to 1st
dosing of IMP.

19. Subjects who received major surgery or interventional treatment within 28 days prior
to 1st dosing of IMP.

20. Subjects who have other active malignancies which are likely to require the treatment.

21. Subjects who have severe cardiovascular disease.

22. Subjects who have uncontrolled or severe illness, including but not limited to ongoing
or active infection (e.g., active COVID-19/SARS-CoV-2 infection, etc.) requiring
therapeutic antibiotics and/or other administration, while SARS-CoV-2 testing is not
mandatory for study entry, and the testing should follow local clinical practice
guidelines/standards.

23. Subjects who have a history of immunodeficiency disease, including other acquired or
congenital immunodeficiency diseases, or organ transplantation, or allogeneic bone
marrow transplantation, or autologous hematopoietic stem cell transplantation.

24. HIV infection, active HBV and HCV infection.

25. Child-bearing potential female who have positive results in pregnancy test or are
lactating.

26. Subjects who have psychiatric illness or disorders that may preclude study compliance;
Subject who is judged as not eligible to participate in this study by the
investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/05/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/11/2023
Sample size
Target
Accrual to date
Final
20
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Alfred - Melbourne
Recruitment postcode(s) [1] 0 0
- Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
LaNova Australia Pty Limited
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety,
Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in
Combination with Toripalimab in Patients with Advanced Solid Tumors
Trial website
https://clinicaltrials.gov/ct2/show/NCT05188664
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Vinod Ganju
Address 0 0
Peninsula & South Eastern Haematology and Oncology Group
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05188664